APAC Orphan Drugs Market Evolution Segmentation and Insight of Trends 2023 to 2028 with Top Countries Data

The APAC Orphan Drugs Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global APAC Orphan Drugs market. This report explores all the key factors affecting the growth of the global APAC Orphan Drugs market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

Get PDF Sample Report Now! @ https://www.prudentmarkets.com/sample-request/141753/

Report Description of the APAC Orphan Drugs Market Analysis

Research Scope and Assumption

The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)
The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis
We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses
All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis
Inflation has not been accounted for in order to estimate and forecast the market
Numbers may not add up due to rounding off

Reason to buy the report:

Facilitate decision-making based on strong current and forecast data for APAC Orphan Drugs Market Analysis
Develop strategies based on the latest regulatory framework
Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market
Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the APAC Orphan Drugs Market Analysis
Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders
To strategically profile key players and comprehensively analyze their market shares and core competencies
We have technically sound team which do a deep dive research and also provide strategy based consulting analysis

APAC Orphan Drugs Market Analysis Executive Summary

Orphan drug can be defined as a pharmaceutical agent specifically designed to treat rare (orphaned) diseases. These diseases differ from usual diseases as their prevalence rate is very low and hence appeal to a very small patient population. Therefore, as compared to non-orphan drugs, these drugs do not guarantee feasible returns on investment. Cost associated with the development of these drugs is higher when compared with non-orphan drugs. The different indications for which orphan drugs are used include lymphoma, leukaemia, cystic fibrosis, etc.

Market Size and Key Findings

The APAC Orphan Drugs Market Analysis size stood at around USD 35.01 billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 8.92% during the forecast period.

The Asia Pacific Orphan Drugs Market is projected to be worth USD 35.01 billion in 2021 and is estimated to grow at a CAGR of 8.92%, reaching USD xx billion by 2028.

Market Dynamics

Market Growth Drivers Analysis

A growing number of patients suffering from various rare diseases related to cancer, cardiovascular problems, and other rare diseases worldwide are outshining the growth rate of the orphan drugs market in the Asia Pacific. These are manufactured specifically with a new formula to treat rare diseases, and hence the demand for this market is overgrowing. Government organizations focused on improving the services in healthcare centers and producing quality drugs favoring the end users, the rise in the concern towards health care among every individual and their prevalence for early diagnosis is elevating the growth rate: of the APAC orphan drugs market.

Market Restraints

Stringent rules and regulations by the government over pharmaceutical companies in concern towards the public's safety, the manufacturing cost of orphan drugs is high compared to the standard drugs, and the lack of professionals in manufacturing drugs with the latest formula is the significant challenges to the market.

COVID-19 impact on APAC Orphan Drugs Market

The novel COVID-19 outburst had enabled certain pharmaceutical markets to be affected moderately due to the postponement of treatment and diagnosis of non-life-threatening diseases. This holds significantly true for individuals suffering from rare diseases as more healthcare and financial resources by various central governments were focused on the fight against the pandemic. This apparently brought down the sales of orphan drugs, negatively impacting the market share.

Competitive Landscape

Key Players

A few noteworthy companies operating in the APAC orphan drugs market profiled in this report are Novartis, GlaxoSmithKline, Roche, Alexion, Sanofi, Bristol Myers Squibb, Pfizer, Vertex, Celgene, and Merck.

Products in Pipeline

June 2020-Chiasma, Inc. announced that the company had received the FDA approval for their product offering of Mycapssa for the treatment of acromegaly, a rare disorder.

June 2020 - Agios Pharmaceuticals, Inc. announced that the company had received the FDA Orphan Drug Designation for their pipeline candidate of Mitapivat for the treatment of Thalassemia.

May 2020-AstraZeneca, and Daiichi Sankyo Company announced that the company had received the FDA Orphan Drug Designation for their product offering of Enhertu (trastuzumab deruxtecan) for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.

Notable Recent Deals

On May 22, 2018, the new NHC (National Health Commission), along with the CNDA (China National Drug Administration), and the three other agencies jointly published the first edition of the Rare Disease List (RDL). The RDL includes 121 diseases and is considered a huge milestone for regulation in rare diseases.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

In Asia, There is an acceleration in the development of legal frameworks in many countries which set forth general criteria to foster the registration and approvals of drugs for the treatment of rare conditions. The regulatory and legal framework of Orphan drugs in Asia is still recent and varies between countries, with some still lacking resources to provide systematic diagnostic or testing for rare conditions.

The Action Plan on Rare Diseases launched in late 2018 by the Asia-Pacific Economic Cooperation is expected to accelerate supportive actions to develop public engagement, disease registries, and patient access to clinical trials, and to reduce enrollment durations.

In 2018, the Asia-Pacific Economic Cooperation (APEC) launched an Action Plan on Rare Diseases, providing a framework for facilitating alignment of domestic policies, best practice systems and enhancing regional collaboration5. The main goal of the plan is to improve the economic and social inclusion of those affected by rare diseases, facilitate diagnostic and nation-wide patient registries, and raise public and political awareness on Orphan diseases issues.

As the Asian pharmaceutical markets grow, so too will opportunities for orphan drugs in Asia. Asian governments are becoming more aware of the importance of orphan drugs, and reimbursements for these products will increase in the future. Each Asian market, however, is different, and one must study each Asian countrys orphan drug regulations and markets to be successful.

Rare diseases need more attention due to lack of proper diagnosis and treatment. Treatment and prevention for rare diseases is considered as no mans land. The EU parliament should provide more benefits like tax incentive, special status, and reimbursement for these orphan drugs. This encouragement can bring in a revolution among the pharmaceutical and biotechnology companies for developing and marketing orphan drugs. EURODIS and other organizations are creating awareness on rare diseases and are also influencing governments in bringing legislation acts for better quality of life for these special people. EURORDIS and National Alliances have announced rare day on February 29th and dedicated this day to special people who are affected by rare diseases. Henceforth, 29th February will be called the rare disease day.

To Know More About COVID-19 Impact On APAC Orphan Drugs Market @ https://www.prudentmarkets.com/sample-request/141753/

APAC Orphan Drugs Market Analysis Segmentation

By Type:

Based on the type, the biologics segment is projected to reap significant gains through 2028. This can be credited to the increasing presence of product offerings classified as biologics. It has been claimed that of the total number of drugs with active orphan status, nearly 39% are biologics. Many new biologics receive Orphan Drug designation for treating rare diseases.

By Therapeutics:

On the basis of Therapeutics, the market includes oncology, hematology, neurology, endocrinology, cardiovascular, respiratory, immunotherapy, and others. The oncology segment held a dominant orphan drugs market share in 2019. The dominance is due to the presence of several oncology drugs in the product development pipelines of key players, and also the presence of a large number of orphan drugs dedicated for the treatment of cancers. The hematology segment is projected to be the second most dominant segment owing to a number of new product launches and increasing positive regulatory approvals. The neurology segment is also anticipated to register a comparatively strong CAGR due to positive developments in the product offerings for key diseases such as multiple sclerosis.

By Country:

In the Asia Pacific, the Chinese orphan drugs market has the fastest growth due to rising approvals for orphan drugs from the Food and Drug Administration, China is the highest populated country globally where the growing demand for orphan drugs and actively promoting the regulation of rare diseases enhance the market. Several key players are interested in developing an orphan drug to treat a rare disease. China is the hub of a rare disease, in this country, most people suffered from infectious diseases. Also, the government has taken the initiatives for development in rare diseases and expanded the orphan drug market in domestic and global markets.

The Indian orphan drugs market is also the fastest-growing country in the APAC region due to rising geriatric patients and growing awareness of these drugs. Increasing various diseases such as cardiovascular disease, endocrinology, lymphatic system disorders, and respiratory disorders will also propel the demand for orphan drugs. There are substantial pharmaceutical industries focused on the innovation and development of orphan drugs into the market.

The Japanese orphan drugs market is expected to register a healthy CAGR in the coming years due to developed infrastructure and innovative technologies in healthcare industries. In addition, the government support and recent FDA approval for orphan drugs will grow the market across the region.

Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ https://www.prudentmarkets.com/discount-request/141753/

The report covers the competitive analysis of the market. As the demand is driven by a buyer's paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global APAC Orphan Drugs Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market.

Strategic Points Covered in Table of Content of Global APAC Orphan Drugs Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the APAC Orphan Drugs market
Chapter 2: Exclusive Summary - the basic information of the APAC Orphan Drugs Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the APAC Orphan Drugs
Chapter 4: Presenting the APAC Orphan Drugs Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the APAC Orphan Drugs market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Any Questions? Feel Free To Enquire Here. We Will put you on the Right Path @ https://www.prudentmarkets.com/enquiry-request/141753/

Free Customization on the basis of client requirements on Immediate purchase:
1- Free country-level breakdown of any 5 countries of your interest.
2- Competitive breakdown of segment revenue by market players.

Customization of the Report:
This report can be customized to meet the client's requirements. Please connect with our sales team (sales@prudentmarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements.

Get ready to Recognize the pros and cons of the regulatory framework, local reforms, and its effect on the Industry. Understand how the Leaders in Intelligent Network are keeping themselves one stage forward with our most up-to-date survey analysis.

In conclusion, the APAC Orphan Drugs Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report.

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.